Skip to main content
Search
Search
India
|
en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
es
Brazil |
pt
Canada |
fr
Canada |
en
Central America |
es
Colombia |
es
Mexico |
es
United States |
en
Venezuela |
es
Australia |
en
Bangladesh |
en
Hong Kong S.A.R. |
zh
India |
en
Indonesia |
en
Japan |
ja
Korea |
ko
Mainland China |
zh
Malaysia |
en
Pakistan |
en
Philippines |
en
Singapore |
en
Taiwan |
zh
Austria |
de
Belgium |
nl
Belgium |
fr
Bulgaria |
bg
Czech Republic |
en
Czech Republic |
cs
Denmark |
da
Estonia |
et
Finland |
fi
France |
fr
Germany |
de
Greece |
el
Hungary |
hu
Ireland |
en
Italy |
it
Latvia |
lv
Lithuania |
lt
Netherlands |
nl
Norway |
no
Poland |
pl
Portugal |
pt
Romania |
ro
Russia |
ru
Serbia |
sr
Slovakia |
sk
Spain |
es
Sweden |
sv
Switzerland |
fr
Switzerland |
de
United Kingdom |
en
Global |
en
Novartis Foundation |
en
Sandoz |
en
Egypt |
en
Israel |
he
South Africa |
en
Turkey |
tr
India
Choose Location
asia-pacific
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
es
Australia |
en
Austria |
de
Bangladesh |
en
Belgium |
nl
Belgium |
fr
Brazil |
pt
Bulgaria |
bg
Canada |
fr
Canada |
en
Central America |
es
Colombia |
es
Czech Republic |
en
Czech Republic |
cs
Denmark |
da
Egypt |
en
Estonia |
et
Finland |
fi
France |
fr
Germany |
de
Global |
en
Greece |
el
Hong Kong S.A.R. |
zh
Hungary |
hu
India |
en
Indonesia |
en
Ireland |
en
Israel |
he
Italy |
it
Japan |
ja
Korea |
ko
Latvia |
lv
Lithuania |
lt
Mainland China |
zh
Malaysia |
en
Mexico |
es
Netherlands |
nl
Norway |
no
Novartis Foundation |
en
Pakistan |
en
Philippines |
en
Poland |
pl
Portugal |
pt
Romania |
ro
Russia |
ru
Sandoz |
en
Serbia |
sr
Singapore |
en
Slovakia |
sk
South Africa |
en
Spain |
es
Sweden |
sv
Switzerland |
fr
Switzerland |
de
Taiwan |
zh
Turkey |
tr
United Kingdom |
en
United States |
en
Venezuela |
es
Menu
About
Novartis in India
Global Drug Development
Strategy
Diversity and Inclusion
People and Culture
Arogya Parivar
India Site Locations
India Country Leadership Team
NIL Board of Directors
Mr. Christopher Snook
Mr. Sanjay Murdeshwar
Mr. Jai Hiremath
Ms. Sandra Martyres
Ms. Monaz Noble
Mr. Sanker Parameswaran
Contact
About
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Diseases
Adverse Event Reporting
Patients and Caregivers
Healthcare Professionals
Healthcare professional country resource
Novartis Pipeline
Adverse Event Reporting
Novartis Clinical Trials
Healthcare Professionals
ESG
Ethical Behavior
Code of Ethics
SpeakUp
Ethics, Risk and Compliance
Access
Environmental Sustainability
Global Health
ESG
Investors | Corporate Governance
Annual General Meeting
Corporate Policies
Financial Results
Stock Exchange Disclosures
Transfer of Shares to IEPF Demat Account
Novartis India Investors Contact
Novartis India Annual General Meeting
Novartis India Board of Directors
Novartis India Investors | Corporate Governance
News
News Archive
Contacts
News
Careers
Career Search
BioCamp
Meet the teams
Personal Growth
Early Talent
Well-being
Diversity and Inclusion
Awards and Recognition
Careers
Coronavirus
Coronavirus
Home
Document
RPT disclosure for the period ended March 31, 2022.pdf
